Some EU member states have temporarily halted distribution of the AstraZeneca/Oxford University (AZ/OU) Covid-19 vaccine, citing thrombotic side-effects.
The halt, even if it is temporary, could threaten any revival in demand for energy products that would come from eased restrictions on mobility and commerce. That in turn could have a knock-on effect for prices, which have risen sharply since the roll-out of vaccines began. The EU is already lagging some other developed regions in its administration of vaccines, including the UK and the US.
The Dutch government paused distribution of the AZ/OU yesterday, expressing concerns about reported cases of post-vaccine thrombosis. It will not administer the vaccine until 28 March. Germany and Italy followed suit today.
AstraZeneca said that as of 8 March there have been 15 events of deep-vein thrombosis and 22 events of pulmonary embolism reported among the 17mn people given its vaccine in the EU and UK, which it said "is much lower than would be expected to occur naturally in a general population of this size".
